Skip to content

US · GENB · BIOTECHNOLOGY

Generate Biomedicines, Inc. (GENB) intrinsic value and stock valuation

$9.54as of 2026-11-21 · Mkt cap 1.84B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Generate Biomedicines, Inc. DCF and intrinsic value

InvestorsCraft values GENB with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from GENB’s statements →

Generate Biomedicines, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Somerville, MA 02143 generatebiomedicines.com

How the business is doing

Fiscal 2024–2025, USD

Revenue
$31.9M
20242025
Net income
-$-203.15M
20242025
Free cash flow
-$-204.13M
20242025
Total equity
-$-623.2M
20242025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2024–2025, USD
20252024
Revenue$31.9M$20.5M
Operating income-$-235.06M-$-196.94M
Net income-$-203.15M-$-173.77M
EPSd-$-4.06M-$-1.36M
Operating cash flow-$-200.62M-$-117.75M
Capital expenditure-$-3.51M-$-3.45M
Free cash flow-$-204.13M-$-121.2M
Total assets$330.2M$518.3M
Total debt$68.5M$77M
Net debt-$-53.12M-$-99.3M
Total equity-$-623.2M-$-435.09M
Cash and short-term investments$221.5M$393.6M
Income statement
20252024
Revenue$31.9M$20.5M
Cost of revenue$0.00$0.00
Gross profit$31.9M$20.5M
Research and development expenses$224.7M$175.3M
Selling, general and administrative expenses$42.3M$42.1M
Other expenses$0.00$0.00
Operating expenses$267M$217.4M
Cost and expenses$267M$217.4M
Interest income$13.7M$18.1M
Interest expense$1.14M$2.12M
Depreciation and amortization$13.2M$15.4M
Ebitda-$-208.49M-$-163.71M
Operating income-$-235.06M-$-196.94M
Total other income/expenses, net$12.3M$15.8M
Income before tax-$-222.8M-$-181.17M
Income tax expense$160K$210K
Net income-$-203.15M-$-173.77M
Weighted average shares outstanding$50.1M$127.5M
Weighted average diluted shares outstanding$50.1M$127.5M
Balance sheet
20252024
Cash and short-term investments$221.5M$393.6M
Net receivables$0.00$310K
Inventory$0.00$0.00
Total current assets$234.4M$407.5M
Property, plant and equipment, net$89M$101.1M
Goodwill and intangible assets$0.00$0.00
Long-term investments$0.00$0.00
Total non-current assets$95.8M$110.8M
Total assets$330.2M$518.3M
Accounts payable$3.84M$5.67M
Short-term debt$15M$16.7M
Deferred revenue$21.2M$42.4M
Total current liabilities$82.2M$86.6M
Long-term debt$53.5M$60.3M
Deferred revenue, non-current$4.51M$15.2M
Total non-current liabilities$871.2M$866.7M
Capital lease obligations$68.5M$77M
Total liabilities$953.4M$953.4M
Common stock$50K$50K
Retained earnings-$-676.29M-$-473.14M
Accumulated other comprehensive income (loss)$110K$120K
Total equity-$-623.2M-$-435.09M
Total investments$99.9M$217.4M
Total debt$68.5M$77M
Net debt-$-53.12M-$-99.3M
Cash flow statement
20252024
Net income-$-222.97M-$-181.38M
Depreciation and amortization$13.2M$15.4M
Stock-based compensation$20.6M$19.5M
Change in working capital-$-14.62M$28.1M
Accounts receivable$310K-$-210K
Inventory$0.00$0.00
Accounts payable-$-2.13M$3.5M
Net cash provided by operating activities-$-200.62M-$-117.75M
Investments in property, plant and equipment-$-3.51M-$-3.45M
Acquisitions, net$0.00$0.00
Net cash used for investing activities$116.8M-$-57.73M
Common stock issued$0.00$0.00
Common stock repurchased$0.00$0.00
Dividends paid$0.00$0.00
Net cash used for financing activities$28.1M$91.3M
Net change in cash-$-55.79M-$-84.15M
Cash at end of period$126M$181.8M
Operating cash flow-$-200.62M-$-117.75M
Capital expenditure-$-3.51M-$-3.45M
Free cash flow-$-204.13M-$-121.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Generate Biomedicines, Inc.

        Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.

        CEO
        Michael T. Nally
        Employees
        312
        Beta
        -0.14

        Explore

        Frequently asked questions

        What is the intrinsic value of Generate Biomedicines, Inc. (GENB)?

        Generate Biomedicines, Inc. (GENB) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GENB undervalued?

        GENB trades at a price of $9.54 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.